Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery

Summary

This single-center, double-blind, randomized controlled trial aims to determine whether oliceridine for patient-controlled intravenous analgesia (PCIA) can significantly reduce the incidence of postoperative nausea, an opioid-related adverse reaction, compared to sufentanil PCIA in patients undergoing cerebellopontine angle (CPA) region surgery. A secondary objective is to compare the postoperative analgesic effects between the two drugs. The study plans to enroll 174 patients (with a calculated sample size of 164 plus 5% for attrition). The primary outcome is the incidence of nausea within 6-48 hours postoperatively. Secondary outcomes include pain scores at rest and during movement within 48 hours, and other exploratory outcomes such as vomiting incidence, time to first flatus/defecation, and gastrointestinal function scores.

Eligibility

Inclusion Criteria:

* Scheduled for elective CPA region surgery with planned PCIA.
* Age 18-65 years.
* ASA physical status I-III.
* Provides written informed consent.

Exclusion Criteria:

* Opioid tolerance (taking opioids ≥1 week, equivalent to oral morphine ≥50 mg/day or oxycodone ≥30 mg/day).
* Severe cardiopulmonary, hepatic, renal, vascular, neurological, hematological, gastrointestinal, or endocrine diseases.
* Postoperative ICU admission with tracheal intubation.
* BMI ≤18.5 or ≥30 kg/m².
* Participation in another clinical trial within 3 months prior to screening.

Conditions5

Interventions2

Related trials

• Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients — Women's Hospital School Of Medicine Zhejiang University

Browse More Trials